Actively Recruiting
Phase III Study of Darolutamide and Stereotactic Dose Escalated Radiotherapy with ADT in Men with Localized High-Risk Prostate Cancer
Led by UNICANCER · Updated on 2026-07-31
700
Participants Needed
6
Research Sites
626 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of darolutamide combined with stereotactic dose escalated prostate radiotherapy in men with localized prostate cancer who have high-risk features for relapse. This phase III international study uses a factorial design to compare different treatment combinations including androgen deprivation therapy ADT and pelvic nodal radiotherapy. The study focuses on patients with at least two high-risk criteria as defined by the National Comprehensive Cancer Network NCCN. Participants will be randomly assigned to one of four groups standard ADT with conventional or moderately hypo-fractionated prostate radiotherapy including pelvic nodal radiotherapy the same treatment plus darolutamide ADT with pelvic nodal radiotherapy plus prostate stereotactic body radiotherapy SBRT or SBRT combined with darolutamide and ADT. Darolutamide is taken orally at 600 mg twice daily for two years. Radiotherapy regimens and SBRT dosing are specified, with SBRT used as a boost in certain arms. ADT is administered for up to two years according to local standards. Throughout the study, participants will have scheduled visits at days 45, 90, 180, and then every three months for checkups and prostate specific antigen PSA monitoring. Imaging with next generation PSMA PET scans will be done at biochemical failure or clinical suspicion and repeated every six months until metastases are found. Researchers will measure metastasis-free survival as the primary outcome, along with other outcomes like progression-free survival and overall survival, with follow-up extending up to 20 years.
CONDITIONS
Brief Title
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Research Team
C
Carine LA
C
Catherine LEGER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here